Compare ASTE & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | ANNX |
|---|---|---|
| Founded | 1972 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.9M | 873.3M |
| IPO Year | 2004 | 2020 |
| Metric | ASTE | ANNX |
|---|---|---|
| Price | $39.13 | $4.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $67.25 | $15.43 |
| AVG Volume (30 Days) | 145.2K | ★ 3.2M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ 784.21 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.04 | N/A |
| Revenue Next Year | $5.88 | N/A |
| P/E Ratio | $80.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.38 | $2.54 |
| 52 Week High | $65.69 | $7.18 |
| Indicator | ASTE | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 41.79 |
| Support Level | N/A | $3.71 |
| Resistance Level | $42.79 | $4.36 |
| Average True Range (ATR) | 1.36 | 0.25 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 17.75 | 52.00 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. The company has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.